Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324616 | 0.91 | MEN1 (0.50) | GPR119NAMPTACACBHRH3MGLL | |
| SCHEMBL23867918 | 0.88 | MGLL (0.47) | GPR119NAMPTACACBHRH3MGLL | |
| SCHEMBL23867867 | 0.86 | GPR119 (0.52) | GPR119NAMPTACACBTP53MGLL | |
| SCHEMBL23867873 | 0.85 | MGLL (0.53) | GPR119NAMPTACACBTP53MGLL | |
| SCHEMBL29469959 | 0.85 | MGLL (0.53) | GPR119NAMPTACACBTP53MGLL | |
| SCHEMBL23867943 | 0.84 | MGLL (0.50) | GPR119NAMPTHRH3MGLL | |
| SCHEMBL29469965 | 0.84 | MGLL (0.50) | GPR119NAMPTHRH3MGLL | |
| SCHEMBL29470013 | 0.83 | MGLL (0.54) | GPR119NAMPTACACBTP53MGLL | |
| SCHEMBL23868007 | 0.83 | MGLL (0.54) | GPR119NAMPTACACBTP53MGLL | |
| SCHEMBL21837021 | 0.83 | RORC (0.49) | GPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | GPR119 254/4885NAMPT 1908/4885ACACB 123/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | GPR119 58/4885NAMPT 1458/4885ACACB 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.